Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  rituximab
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 537 for your search:
Start Over
Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 40 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 102-12, NCT00090038
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL03, NCT00199004
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 to 120
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO19872, NCT00430352
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO22468, 2009-012072-28, NCT01056510
A Study of MabThera (Rituximab) in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia And Favorable Somatic Status
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25136, NCT01271010
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25137, NCT01283386
Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: Other
Protocol IDs: RJ-2010-56, NCT01358253
Rituximab+Standard CHOP vs Rituximab+bi-Weekly CHOP for Untreated Stage III/IV Low-Grade B-Cell Lymphoma (JCOG0203)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 20 to 69
Sponsor: Other
Protocol IDs: JCOG0203, C000000033, NCT00147121
Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IL2NHL03, UCLA-0302013, CHIR-IL2NHL03-A01, NCT00045877
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-DLC-001, NCT01197560
Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP
Phase: Phase III, Phase II
Type: Natural history/Epidemiology, Supportive care
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: 201010HBV, NCT01210287
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 15 to 65
Sponsor: NCI, Other
Protocol IDs: CDR0000065658, S9704, U10CA032102, SWOG-S9704, CAN-NCIC-LY11, CALGB-59903, ECOG-S9704, LY11, NCT00004031
Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: SAKK 35/98, SWS-SAKK-35/98, ICR-35/98, EU-98009, NCT00003280
Phase III Randomized Study of IDEC-Y2B8 Radioimmunotherapy Versus Rituximab Immunotherapy for Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: IDEC-106-04, MAYO-977802
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-2012-02279, AMC-010, CPMC-IRB-9691, CWRU-AMC-1400, UCLA-9810029, CDR0000066666, NCT00003595
Phase III Study of IDEC-Y2B8 in Patients With Progressive Follicular B-Cell Non-Hodgkin's Lymphoma That is Refractory to Prior Rituximab Therapy
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IDEC-106-06, MAYO-987804, UCLA-9808026
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 19 and over
Sponsor: NCI, Other
Protocol IDs: 447-97, P30CA036727, UNMC-447-97, UCLA-HSPC-9812071, NCI-G99-1601, NCT00004112
Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-20981, ALLG-NHLLOW4, BNLI-EORTC-20981, HOVON-H039, CAN-NCIC-LY7, NORDIC-EORTC-20981, LY7, NCT00004179
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068321, U10CA032102, S0016, CALGB-50102, SWOG-S0016, ECOG-SWOG-S0016, NCT00006721
Start Over